Provider Newsflash
September 2024

FDA Recall – Gilead Sciences, Inc.

Purpose of this communication:

- We are writing to inform you that Gilead Sciences, Inc. (Nasdaq: GILD) announced it is issuing a voluntary recall of lot # 47035CFA of Veklury® (remdesivir) 100 mg/vial with an expiration date of 11/2025 distributed to wholesalers 7/16/2024 to 8/7/2024 for Injection, to the consumer level. Gilead received a customer complaint and confirmed the presence of a glass particle in the vial during the company's investigation.

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/gilead-issues-voluntary-nationwide-recall-one-lot-veklury-remdesivir-injection-100-mgvial-due?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the replacement of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.